Wellcome Trust Awards EBI $10M to Manage Trace Sequence Archive
The UK’s Wellcome Trust has awarded the European Bioinformatics Institute €6.3 million ($10 million) through 2012 to manage an international archive of raw DNA sequence data, EBI said this week.
The EBI will maintain the resource, called the Trace Archive, in collaboration with the National Center for Biotechnology Information in the US.
The Trace Archive, available here, currently contains more than 1,770 million traces from 1,262 species, which is the equivalent of 100 terabytes of data.
The resource will enable researchers to reanalyze DNA sequence rather than resequencing samples — an option that can be up to 1,000 times cheaper than regenerating sequence, EBI said.
The Trace Archive is a collaborative effort between Ewan Birney and Paul Flicek at the EBI. Flicek, head of the Vertebrate Genomics Team, said in a statement that the EBI’s “first task is to incorporate the novel types of data generated by new sequencing technologies, for example, short reads.”
EBI said that the amount of data in the archive is expected to double over the next four years.
TGen, Hopkins Bioinformatics Groups to Benefit from NIH NCRR Awards
The Translational Genomics Research Institute and Johns Hopkins University have each been awarded $2 million to buy supercomputers for biomedical applications under the National Institutes of Health’s High-End Instrumentation program.
The grants, awarded through the NIH’s National Center for Research Resources, are aimed at helping researchers buy tools that cost more than $750,000. NCRR provides up to a total of $2 million per award.
TGen and Hopkins were among 20 recipients of the current round of awards, which were announced this week and totaled $33 million.
TGen said it will use its $2 million award to buy supercomputing equipment for translational research aimed at identifying biomarkers for several common diseases, while Hopkins will use its $2 million award to buy a large-memory cluster computer for its Institute for Computational Medicine to support the development of computational models and algorithms for disease diagnosis and treatment.
TGen said that its new system will double its supercomputing capabilities, though it did not provide details of the computer that it plans to purchase.
Hopkins, meantime, said that it plans to purchase a 256-node dual quad-core cluster computer with 1 petabyte of storage. It plans to install the system in early 2009.
Pfizer Signs Global Deal for Genomatix Software and Databases
Genomatix Software said this week that Pfizer has licensed use of its software and databases for use by Pfizer Pharmaceuticals’ sites around the world.
The Munich, Germany-based bioinformatics company said that Pfizer will use the software and data content “to help understand the molecular basis of how their potential drug targets may be co-regulated with other important targets, producing potential desirable or unwanted side effects.”
Financial terms of the license were not disclosed.
IGC Taps LabVantage Sapphire as Biobanking LIMS for Cancer Genome Atlas
The International Genomics Consortium will use LabVantage’s Sapphire lab information management software to handle biobanking needs for the Cancer Genome Atlas pilot project, the company said this week.
IGC, a Phoenix, Ariz.-based non-profit, is running the biobank for TCGA’s Human Cancer Biospecimen Core Resource component. TCGA is a joint project of the National Cancer Institute and the National Human Genome Research Institute.
The Sapphire solution is used in all the steps of biorepository management including informed consent, clinical data collection, sample and data collection, pathology review, and biomolecule extraction and distribution.
Financial terms of the agreement were not released.
Veeda's India, UK Research Labs to Use Thermo Fisher's LIMS
Thermo Fisher Scientific said this week that Veeda Clinical Research will use its lab information management system in Veeda’s facilities in Ahmedabad, India, and in Oxford, UK.
Veeda’s Ahmedabad branch is already using Thermo Fisher’s Watson LIMS, while the UK lab is currently in the validation process and should be using the software “in the near future,” Thermo said.
The Anglo-Indian company Veeda, which provides clinical pathology, biomarker, and bioanalytical services, also has offices in Belgium, Germany, France, and the US.
The Ahmedabad lab offers services for small molecule pharmacokinetics, and the UK facility offers biomarker, large molecule pharmacokinetics, immunogenicity assay development, validation, and sample analysis.
Financial terms of the agreement were not released.
GeneGo Certifies U of Miami’s Miller School of Medicine as Center of Excellence
GeneGo said this week that it has certified the University of Miami Miller School of Medicine as a GeneGo Center of Excellence.
Under the terms of the agreement, Miller School of Medicine researchers will have access to GeneGo's MetaCore, as well as training and advanced support.
The center “will provide a pathway analysis environment and support for all the school's researchers” and will also act as a training facility for GeneGo at the University of Miami, the company said.
Earlier this month, GeneGo signed a similar agreement with Yale University’s Keck Microarray Center [BioInform 07-11-08].
Simulations Plus Reports 13 Percent Increase in Q3 Revenues
Simulations Plus this week reported a 12.8 percent increase in revenues for its third fiscal quarter, accompanied by a slight dip in net income.
For the three months ended May 31, revenues rose to $3 million from $2.6 million in the comparable period of 2007. Revenues for the company’s pharmaceutical software and services business rose 19 percent to $2 million from $1.6 million in the prior-year quarter while revenues for the firm’s Words+ subsidiary increased 2.2 percent to $994,000 from $972,000 in the third quarter of fiscal 2007.
R&D spending dipped slightly to $222,241 from $226,749, while total operating expenses rose to $1.2 million from $1.1 million.
Net income fell to $752,661 from $782,292 in the comparable period of 2007.
The company ended the quarter with $6 million in case and cash equivalents.
In a statement, Walt Woltosz, chairman and CEO of Simulations Plus, said that the company is “continuing to seek acquisitions and we're making investments on new product developments and increasing our marketing and sales efforts.”
Georgetown U Med Center Using Syngene Dymension 2D Gel Analysis Software
Syngene said this week that Georgetown University Medical Center is using its Dymension 2D image analysis software for breast cancer drug discovery research.
Researchers in GUMC’s Lombardi Comprehensive Cancer Center are using the software to analyze images of Coomassie Blue stained proteins derived from breast cancer cell lines after treatment with an 8-quinolinyl histone deacetylase inhibitor, Syngene said.
Financial terms of the agreement were not disclosed.